Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Ipsen has set aside the two drug candidates it picked up from a 2023 acquisition of liver disease specialist Albireo, with one of the assets discontinued entirely.